Sexual function and metabolic/hormonal changes in women using long-term hormonal and non-hormonal contraceptives: a pilot study

Moreira, Igor Fernando de aquino; Bianchini, Maria Passos; Moreira, Gabrielle Rodrigues Campos; Almeida, Alessandra Maciel; Rezende, Bruno Almeida

doi:10.1186/s12905-020-01107-1

Cited by 12 publications

(3 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Di Carlo et al [122] demonstrated that in the short term (first three months of treatment), patients experienced a temporary reduction of vitality, mental health, social functioning, and emotional role functioning; thereafter, an improvement in general health status and physical role status was observed [122]. Some data suggested a positive Nexplanon influence on sexual function (increase in pleasure, personal initiative, and orgasm) with a secondary decrease in anxiety and discomfort [101]; conversely, other authors suggest that ENG implants had a negative influence on sexual function, probably by blocking ovarian function and thus reducing the production of androgens and oestrogens [123]. A rare case of secondary etonogestrelrelated anorgasmia was described [124].…”

Section: Nexplanonmentioning

confidence: 99%

Safety and Benefits of Contraceptives Implants: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

Progestin-only contraceptive implants provide long-acting, highly effective reversible contraception. We searched the medical publications in PubMed, CENTRAL, and EMBASE for relevant articles on hormonal implants published in English between 1990 and 2021. Levonorgestrel (LNG) 6-capsule subdermal implants represented the first effective system approved for reversible contraception. The etonogestrel (ENG) single rod dispositive has been widely employed in clinical practice, since it is a highly effective and safe contraceptive method. Abnormal menstrual bleeding is a common ENG side effect, representing the main reason for its premature discontinuation. Emerging evidence demonstrated that it is possible to extend the use of the ENG implant beyond the three-year period for which it is approved. The ENG implant could be an effective and discrete alternative to the IUD in young girls, such as post-partum/post-abortion. Implants should be inserted by trained skilled clinicians who previously provide adequate counselling about their contraceptive effect, benefits, and any possible adverse events. More studies are needed to validate the extended use of the ENG implant for up to 5 years.

show abstract

Section: Nexplanonmentioning

confidence: 99%

Safety and Benefits of Contraceptives Implants: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…This study has highlighted the fact that progestogen contraceptives may differ considerably and unpredictably in their effects on behaviour and menstruation and cannot be considered similar in terms of behavioural effects and effects on HIV risk. For example, the etonorgestrel implant has been associated with impaired sexual function, thought to be related to suppression of estrogen and testosterone [ 20 ], but we do not have robust data comparing this effect with other methods. Intramuscular norethisterone enanthate has many similar behavioural effects to DMPA-IM, but less glucocorticoid and immunosuppressive effects] [ 21 , 22 ].…”

Section: Discussionmentioning

confidence: 99%

Sexual behaviour among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Data from the ECHO randomized trial

Hofmeyr,

Singata-Madliki,

Batting

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Background Contraceptive use has complex effects on sexual behaviour and mood, including those related to reduced concerns about unintended pregnancy, direct hormonal effects and effects on endogenous sex hormones. We set out to obtain robust evidence on the relative effects of three contraceptive methods on sex behaviours, which is important for guiding contraceptive choice and future contraceptive developments. Methods This is a secondary analysis of data from the Evidence for Contraceptive Options and HIV Outcomes (ECHO) randomized trial in which 7,829 HIV-uninfected women from 12 sites in Eswatini, Kenya, South Africa and Zambia seeking contraception were randomly assigned to intramuscular depot-medroxyprogesterone acetate (DMPA-IM), the copper intrauterine device (Cu-IUD) or the levonorgestrel (LNG) implant. Data collected for 12 to 18 months using 3-monthly behavioural questionnaires that relied on recall from the preceding 3 months, were used to estimate relative risk of post-baseline sex behaviours, as well as sexual desire and menstrual bleeding between randomized groups using modified Poisson regression. Results We observed small but generally consistent effects wherein DMPA-IM users reported lower prevalence of specified high risk sexual behaviours than implant users than Cu-IUD users (the ‘>‘ and ‘<‘ symbols indicate statistically significant differences): multiple sex partners 3.6% < 4.8% < 6.2% respectively; new sex partner 3.0% < 4.0% <5.3%; coital acts 16.45, 16.65, 17.12 (DMPA-IM < Cu-IUD); unprotected sex 65% < 68%, 70%; unprotected sex past 7 days 33% <36%, 37%; sex during vaginal bleeding 7.1%, 7.1% < 8.9%; no sex acts 4.1%, 3.8%, 3.4% (DMPA-IM > Cu-IUD); partner has sex with others 10% < 11%, 11%. The one exception was having any sex partner 96.5%, 96.9% < 97.4% (DMPA-IM < Cu-IUD). Decrease in sexual desire was reported by 1.6% > 1.1% >0.5%; amenorrhoea by 49% > 41% >12% and regular menstrual pattern by 26% <35% < 87% respectively. Conclusions These findings suggest that women assigned to DMPA-IM may have a modest decrease in libido and sexual activity relative to the implant, and the implant relative to the Cu-IUD. We found more menstrual disturbance with DMPA-IM than with the implant (and as expected, both more than the Cu-IUD). These findings are important for informing the contraceptive choices of women and policymakers and highlight the need for robust comparison of the effects of other contraceptive methods as well.

show abstract

“…40 Etonogestrel-releasing subdermal implant (ENG-implant) ENG is a subcutaneous implant that systematically releases a synthetic substance similar to progesterone. 45 In a study evaluating the effectiveness of the ENG-implant compared to the 52-mg LNG-IUS in the control of endometriosis-related pelvic pain, both contraceptives were shown to significantly improve dysmenorrhea, pelvic pain and HRQoL. 46 Subdermal implants (ENG-implant 68 mg with a life span of 3 years) have been found to be as effective in pain relief over 12 months of use as DMPA.…”

Section: Medroxyprogesterone Acetatementioning

confidence: 99%

Progestins and combined oral contraceptives in the hormonal treatment of endometriosis – a review

Rojek¹

2023

Eur J Clin Exp Med

View full text Add to dashboard Cite

Introduction and aim. Endometriosis is a common inflammatory disease affecting 6-10% of women of reproductive age. It is defined as the growth of endometrial-like tissue outside the uterine cavity. Dysmenorrhea, pelvic pain, dyspareunia and infertility are the main symptoms of endometriosis patients. Endometriosis treatment methods can be broadly divided into surgical and pharmacological. Currently, hormonal drugs are often used for women with endometriosis to relieve bothersome symptoms. The aim of this article is to review new publications presenting the effectiveness as well as side effects of the use of progestins and combined oral contraceptives in the hormonal treatment of endometriosis. Material and methods. A review of the literature regarding progestins and combined oral contraceptives in the treatment of endometriosis was performed using the PubMed database. In the end, 67 articles were included in this review. Analysis of the literature. Progestins and combined oral contraceptives significantly reduce dysmenorrhea, dyspareunia and pelvic pain in women with endometriosis. However, there is a risk of potential side effects, which should be taken into account when choosing a therapy for each patient individually. Conclusion. Endometriosis is a chronic disease that has a significant impact on the health-related quality of life of patients. When choosing a treatment, many aspects should be considered, primarily the patient’s preferences, drug tolerance and safety. Further drug research is needed to determine the most effective treatment for endometriosis.

show abstract

Sexual function and metabolic/hormonal changes in women using long-term hormonal and non-hormonal contraceptives: a pilot study

Cited by 12 publications

References 45 publications

Safety and Benefits of Contraceptives Implants: A Systematic Review

Safety and Benefits of Contraceptives Implants: A Systematic Review

Sexual behaviour among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Data from the ECHO randomized trial

Progestins and combined oral contraceptives in the hormonal treatment of endometriosis – a review

Contact Info

Product

Resources

About